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Abstract
The !3-secretase (BACE1) is initially synthesized as a partially
act ive zymogen contain ing a prodomain which can be fur-
the r activated th rough proteolytic cleavage of the prodo-
main by a fu rin-Iike protease.The active site of BACEl is large
and although a number of high-affinity active-site inh ibitors
of BACEl have been described, most of these compounds
are large, polar and do not cross the blood-brain barrie r.
However, it may be possible to target other regions of the
protein wh ich regulate BACEl allosterically. We have found
that proBACEl can be stimulated by relatively low concen-
trations (e.g. 1 u .q/ rnl) of heparin . Heparin initially increases
proBACEl activity, probably by binding to the prodomain,
which decreases steric inhibiti on at the active site. However,
the heparin-activated zymogen also unde rgoes autocataly-
sis, wh ich ultimately leads to a loss of enzyme activ ity. We
speculate that proBACEl can be regul ated by endogenous
heparan sulfate proteoglycans and t hat drugs wh ich target
this interact ion may have value in the t reatment of Alzhei-
mer's disease. Copyrig ht e 200 8 S. Karger AG, Base l
The f3- secretase (BACEl) is an important target for
Alzheimer's disease (AD) drug development because the
enzyme cata lyzes the first step in the production of 13-
amy loid, and because the enzy me may have on ly a lim-
ited range of substrates in vivo [1]. BACE1 belongs to the
family of aspartic pro teases, but it differs from many
family members by being mem brane anchored. Full-
length BACEl contains 501 amino-acid residues includ-
ing a signa l pep tide sequence and a 24-resid ue prodo-
ma in. During its maturation in the secretory pathway,
BACE1 undergoes complex N-linked glycosylation [2] .
Evidence suggests that proBACEl becomes fully glyco-
sylated first and then the prodomain, which is important
for the proper folding of the protease domain, is removed
by a furin-like protease, possibly in the trans-Golgi net-
work (TGN) [3]. However, the exact subcell ular compart-
ments in which the pro domain is cleaved off have not yet
been established. Unlike many aspartic proteases, the
prodomain does not completely suppress activity of the
enzyme [4]. Therefore, proBACEl may have an enzymic
function in vivo.
BACE1 may be a suitable target for drug development
because BACE1 knockout mice are viable [5]. Apart from
a hypomyelination phenotype, caused by the fact that
neuregulin 1 (a BACEl substrate) is important for oligo-
dend rocyte development [6], BACEl knockout mice have
no major neuropathological abnormalities. However, the
development of drugs which inhibit BACE1 at the active
site has been difficult. The active site of BACEl is large
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Fig. 1. Model of the activation of pro-
BACEI by heparin. ProBACEI has a lower
enzymic activity than mature BACEI. The
binding of heparin to a cluster of positive-
ly charged residues in the prodomain re-
sults in a conformational shift which re-
lieves steric hindrance by the prodomain
at the active site.
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and many drugs which inhibit the protease by binding to
the active site are large and cross the blood-brain barrier
poorly [7] . For this reason, the identification oflow-mo-
lecular-weight BACEI inhibitors is of considerable im-
portance.
BACE1 Is a Heparin -Binding Protein
Scholefield et al. [8] first reported that BACEl can
bind to and be inhibited by heparin and that it can be co-
immunoprecipitated with heparan sulfate (HS) proteo-
glycans. HS is a sulfated glycosaminoglycan commonly
attached to various core proteins via an O-linked tetra-
saccharide ofxylose-galactose-galactose-glucuronic acid
[9]. Heparin is a highly sulfated form ofHS. As a number
ofproteases are known to be regulated by HS binding, the
result of Scholefield et al. [8] suggests that BACEI may
also be regulated by HS in vivo.
Our studies show that heparin's effects on BACEl are
complex [10] . High concentrations of heparin (l00 fLg /
ml) inhibit the enzyme, whereas lower concentrations
(I ug/ml) stimulate activity. The stimulatory effect re-
quires the presence of the prodomain and our data sup-
port the view that heparin can bind directly to the prodo-
main. For example, a peptide homologous to the prodo-
main was found to bind to heparin and our studies show
that mature (prodomain cleaved) BACEI cannot be acti-
vatedby heparin. It seems likely that the binding of hep-
arin to the prodomain activates the enzyme by removing
sterichindrance at the active site (fig. 1).
Low concentrations (l u.g/ml) of heparin were also
found to stimulate autocatalytic cleavage of proBACEl
[10]. The amount ofautocatalytic cleavage correlates with
inactivation of the enzyme that can be observed at longer
time periods of incubation. Analysis of the products of
cleavage by tandem mass spectrometry revealed that one
of the heparin-stimulated autocatalytic cleavage sites was
at phenylalanine-99, close to one of the act ive-site aspar-
tate residues (aspartate-93) which are critical for enzyme
activity. It is possible that cleavage at this position (or at
another position close to the active site) may account for
the loss of enzyme activity.
Can Glycosaminoglycans Be Used for the Treatm ent
of AD?
Assembly of HS proteoglycans is known to begin in
the lumen of the endoplasmic reticulum, and the final
stages of this assembly (sulfation) occur in the TGN [11] .
ProBACEl is also synthesized in the endoplasmic reticu-
lum and processed through the Golgi apparatus. Remov-
al of the prodomain of BACEI by furin is likely to occur
in the TGN or in later membrane compartments [12] .
Therefore, as f3-secretase processing of amyloid precur-
sor protein (APP) can occur in compartments where en-
zymatically active proBACEl may reside, such as the en-
doplasmic reticulum and the TGN [13],it may be hypoth-
esized that proBACEl has a direct role in APP processing.
Furthermore, as HS proteoglycans are likely to be in the
same compartments as proBACEl, they may help to reg-
ulate proBACEl cleavage of APP.
Leveugle et al. [14] found that exogenously added hep-
arin can stimulate f3 -secretase cleavage ofAPP in cell cul-
ture. This finding raises the possibility that low-rnolecu-
au
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lar-weight heparin mimetics may block the inte raction of
proBACEl with endogenous HS proteoglycans and there-
by inhibit f3-amyloid pro duction. The idea that glycos-
aminog lycans may be useful for the treatment of AD is
not new.A number of studies have shown that glycosami-
noglycan s are associated with amyloid deposits [15] and
that th ey can accelerate amyloid fibril formation or amy-
loid deposition [16] . Unlike many highly charged mole-
cules, glycosam inoglycan s can be actively taken up by
cells [17] and th ey can be absorbed orally [18]. Further-
more, some low-molecular-weight form s ofHS may cross
the blood-brain barrier [19] . For example, peripheral ad-
Refere nces
ministration of a low-molecular-weight heparin, enoxa-
parin, has been shown to reduce the amyloid burden in
APP transgenic mice [20], although the mechanism by
which th is occurs is unclear.
In summary, our work indicates that heparin can bind
to the pro domain of BACEl. This binding activates the
enzyme , but also increases autocatalytic cleavage of
BACEl. On the basis of these findings, we speculate that
proBACEl may interact with endogenous HS proteogly-
cans, rais ing the possibility that interfering with thi s en-
dogenous interaction may disrupt BACEl cleavage of
APP.
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